Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Single-session panretinal PRP (SS-PRP), Multiple-session panretinal PRP (MS-PRP).
- Who it may be relevant to
- Registry conditions: Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetic Retinopathy Visually Threatening, Diabetic Macular Edema. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Single Session vs Multiple-Session Panretinal Photocoagulation With Navigated Laser in Proliferative Diabetic Retinopathy - The SMART-PRP Study
Overview
Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.
Detailed description
Proliferative diabetic retinopathy (PDR) is a well-known complication for both type 1 and type 2 diabetes mellitus (DM) and it is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR, established more than four decades ago by the Diabetic Retinopathy Study (DRS), is panretinal photocoagulation (PRP). The treatment goal is to halt the progression of PDR by destroying parts of the peripheral retina in a pattern fashion and hence preserving the visually important central macular region. The tissue destruction reduces the area of ischemia and reduces the production of vascular endothelial growth factor (VEGF), which drives the formation of neovascular proliferations. In the management of PDR, panretinal photocoagulation (PRP) stands as a cornerstone treatment. In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The choice between these approaches often depends on the practitioner's preference, patient characteristics, and specific clinical circumstances.
Although both single-session and multiple-session PRP are employed in practice, there's an ongoing debate regarding their comparative safety and effectiveness. Older studies suggest a heightened risk of diabetic macular edema (DME) with single-session PRP, while newer research, particularly those involving milder laser techniques, indicates that the risk might be similar regardless of the number of sessions. This inconsistency in findings underscores the need for further research and the investigators aim to shed light over this with this prospective, controlled and randomized interventional study.
Interventions
- Procedure Single-session panretinal PRP (SS-PRP)
Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit. - Procedure Multiple-session panretinal PRP (MS-PRP)
Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
Primary outcome measures
- Central subfield retinal thickness (CRT) [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Vessel Perfusion Density (VPD) [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Vessel Length Density (VLD) [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Foveal Avascular Zone (FAZ) [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Lesion size [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Macular volume [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Venular saturation [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Arteriolar saturation [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Retinal diameter [Time frame: Baseline and 1, 3 and 6 months after treatment]
- Venular diameter [Time frame: Baseline and 1, 3 and 6 months after treatment]
Eligibility criteria
Inclusion criteria
- Age > 18 years.
- Patients with type 1 or type 2 Diabetes Mellitus with newly diagnosed Proliferative Diabetic Retinopathy, PDR.
- Visual acuity ≥ 0.1 Snellen.
- CRT of less than 300 micrometer measured by OCT without cysts in the neuroretina.
- Clear media and adequately dilated pupil for PRP.
Exclusion criteria
- Intraocular surgery within the last 4 months or planned within the next 3 months.
- Previous or current center-involved diabetic macular edema (Ci-DME).
- Previous PRP, intravitreal treatment (IVT), or macular laser treatment in study eye.
- Treatment with medications known to risk macular edema.
- Media opacity preventing adequate PRP.
- General medical condition making office laser treatment very difficult or impossible.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Sweden · 1 center
- Ögonmottagning Mölndal/SU — Mölndal
Identifiers
NCT: NCT06549023 · SMART-PRP